Skip to main content
Mersana Therapeutics, Inc. logo

Mersana Therapeutics, Inc. — Investor Relations & Filings

Ticker · MRSN ISIN · US59045L1061 LEI · 529900VWD5VDZ7PVOS22 US Manufacturing
Open in API
Filings indexed 700 across all filing types
Latest filing 2021-11-15 Regulatory Filings
Country US United States of America
Listing US MRSN

About Mersana Therapeutics, Inc.

https://www.mersana.com/

Mersana Therapeutics, Inc. is a clinical-stage company focused on discovering and developing life-changing antibody-drug conjugates (ADCs) for patients fighting cancer. The company utilizes its proprietary and differentiated ADC platforms, which incorporate both cytotoxic and immunostimulatory payloads, to develop its pipeline. These platforms are designed to customize and optimize ADCs, aiming to overcome the limitations of first-generation technologies by improving efficacy and tolerability. Mersana is advancing a portfolio of ADC candidates to address unmet medical needs in oncology.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2021
Regulatory Filings Classification · 90% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, or references to specific report types, fiscal periods, or regulatory bodies. Due to the lack of discernible information and the inability to identify the nature of the document, it cannot be classified into any specific filing category based on the given definitions. According to the rules, when a document does not neatly fit into any specific category, it should be classified as a Regulatory Filing (RNS) as a fallback category.
2021-11-15 English
S-3
Capital/Financing Update Classification · 95% confidence The document is a Form S-3 registration statement filed with the U.S. Securities and Exchange Commission. It is a registration statement under the Securities Act of 1933 used for registering securities for public offering. The text includes details about the registrant, securities to be registered, and legal disclaimers. It is not an annual report, earnings release, or any other financial report but a capital markets filing related to securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), indicating it is the actual filing, not just an announcement. Hence, the classification is CAP with high confidence.
2021-11-09 English
10-Q
Interim / Quarterly Report Q3 2021
2021-11-09 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 9, 2021, by Mersana Therapeutics, Inc. It announces the release of a press release containing financial results for the third quarter ended September 30, 2021. The text explicitly states that the press release is furnished as an exhibit and that the Form 8-K is a current report. The document does not contain the full financial statements or detailed financial analysis itself but rather announces the earnings release. The length of the document is 3741 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this filing is best classified as an Earnings Release (ER) announcement within a Form 8-K.
2021-11-09 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement, specifically a Loan and Security Agreement involving term loans and financing details. It also mentions the termination of a prior loan agreement and creation of a direct financial obligation. The document is not a full financial report but an announcement of financing activity. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is 8546 characters, which is consistent with a detailed 8-K filing. No other category fits better as this is not an earnings release, annual report, or management discussion. Hence, the classification is CAP with high confidence.
2021-10-29 English
SC 13G
Major Shareholding Notification
2021-09-16 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.